James Harbeck jharbeck at SYMPATICO.CA
Thu Nov 19 04:11:12 UTC 2009

I would not vote this word "most likely to survive," but it did land
mewling in my inbox today; see the following, from the pharmacy
business news email FirstWord:

Markets are changing, profits are dropping and bottom lines are
getting harder to predict. Global growth led by developed economies
like the US, Canada, Western Europe and Japan is shrinking, with
their contribution set to hit an all-time low of 16 per cent this
year. Everywhere you look, the evidence is clear: today's
pharmaceutical industry will not look the same as tomorrows.

Yet while traditional pharma markets contract, others are poised not
just to grow, but dominate. So-called "pharmerging" regions such as
Brazil, India, Turkey, Mexico, Russia and South Korea are forecast by
IMS Health to grow - and grow - by an astonishing 51 per cent this

And leading the pack is the biggest country on the planet. With 1.3
billion citizens, an aging population and a voracious appetite for
Western lifestyles, China is expected to see annual growth of more
than 20 per cent, year-on-year.

In Pharmerging Markets: China - leaders, followers and latecomers,
FirstWord critically analyzes the social, political and economic
drivers behind the nation's promising market position in the changing
global landscape. The first in a series on pharmerging regions, the
40-plus page report tracks the innovators who moved early in China
and are now reaping 25 per cent yearly growth, as well as the work of
the followers - and those who have yet to fully grasp the opportunity.

When I first look at "pharmerging" I think not of emerging but of
merging, something big pharma companies do even more than, say,
university theatre students.

James Harbeck.

The American Dialect Society -

More information about the Ads-l mailing list